Derms on Drugs takes on the AAD late breaking research, Part 2

Late-breaking abstracts from the American Academy of Dermatology meeting reveal significant advancements in dermatological therapeutics and diagnostic technology. Combination therapies, such as Ixekizumab with Terzapatide, demonstrate superior efficacy in managing psoriatic arthritis, while new JAK inhibitors like Povorcitinib and Brepocitinib show promise for Hidradenitis Suppurativa and dermatomyositis, respectively. Research into novel biologics like Radimicabart suggests high response rates for atopic dermatitis, and intralesional PD-1 therapy offers a targeted approach for squamous cell carcinoma. Diagnostic innovation continues with AI-driven tools like Derm Plus, which aim to improve lesion classification accuracy. Despite these clinical gains, practical challenges remain regarding the cost and implementation of systemic treatments for conditions like keloids. These findings collectively emphasize a shift toward more targeted, potent, and technologically integrated interventions for complex skin diseases.